Development of severe sclerotic chronic GVHD during treatment with dasatinib.

摘要

In the recently published letter to the editor, Breccia et al. described a Philadelphia chromosome positive (Ph + ) CML patient who relapsed after haploidentical BMT, and in whom low-dose dasatinib restored the molecular response and improved hepatic chronic GVHD (cGVHD). Moreover, several other recent papers described patients with various fibrotic/sclerotic cGVHD manifestations benefiting from imatinib. Stadler et al. proposed that stronger effects in cGVHD-induced fibrosis might be possible with the newer tyrosine kinase inhibitors (TKIs).